Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Skyworks Solutions Inc (SWKS) Price & Performance

Heron Therapeutics IncTrade
Skyworks Solutions IncTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Skyworks Solutions Inc — how do they compare? Heron Therapeutics Inc trades at $0.34 (market cap $61.47M), while Skyworks Solutions Inc trades at $68.8 (market cap $10.28B). The key difference: Skyworks Solutions Inc is far larger — about 167.2× Heron Therapeutics Inc's market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HRTXSWKS
Market Cap
$61.47M$10.28B
Sector
HealthTechnology
52-Week High
$1.49$83.40
52-Week Low
$0.32$52.50
Enterprise Value
$168.21M$10.16B
Dividend Yield
4.13%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.

The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.

Skyworks Solutions Inc

Skyworks Solutions (SWKS) trades at $68.17, down 0.9% today, with a bullish technical signal from moving averages and recent earnings beats in Q2 2026. The stock shows strong institutional buying interest and a 58% analyst buy rating, though revenue has declined from $5.5B in 2022 to $4.1B in 2025. The pending Qorvo combination and AI data center growth present strategic opportunities, but profitability margins have compressed, and a legal investigation adds near-term uncertainty.

The outlook is cautiously optimistic, supported by earnings consistency and diversification into automotive and AI markets, but investors face risks from integration execution, margin pressure, and regulatory scrutiny. The consensus price target of $66 suggests limited upside, requiring careful monitoring of merger progress and quarterly performance against expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Skyworks Solutions Inc

Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.

Read more on SWKS